产品名称

TAK 165 - Mubritinib

产品货号

Axon 2053 CAS [366017-09-6] MF C25H23F3N4O2MW 468.47 Purity: 99% Soluble in DMSO Description Highly selective, potent and irreversible human epidermal growth factor receptor 2 (HER2 aka ErbB2) antagonist (IC50: 6 nM); recommended tool compound for HER2 selective inhibition References Certificates Categories Extra info J Nagasawa et al. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int. J. Urol. 2006, 13(5), 587-592. S Yoshida et al. Tak-165, a selective inhibitor of HER2 tyrosine kinase: 2. Mechanism of antitumor activity on HER2 signal transduction pathway. Proc. Am. Assoc. Can. Res. 2002, 43, 3898. JC Uitdehaag et al. A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets. Br. J. Pharmacol. 2012, 166, 858–876. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology ErbB2-HER2 RTK class I; EC 2.7.10.1 ErbB2/HER2 kinase inhibitor Chemical name (E)-4-((4-(4-(1H-1,2,3-triazol-1-yl)butyl)phenyl1H-1,2,3-triazol-1-yl)butyl)phenoxy)methyl)-2-(4-(trifluoromethyl)styryl)oxazole Parent CAS No. [366017-09-6] Order Size Unit Price Stock 5 mg €65.00 In Stock

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

TAK 165 - Mubritinib

Based on 12 reference(s) in Google Scholar 9 10 12

Axon 2053

CAS [366017-09-6]

MF C25H23F3N4O2
MW 468.47

Purity: 99%
Soluble in DMSO

TAK 165

Description

Highly selective, potent and irreversible human epidermal growth factor receptor 2 (HER2 aka ErbB2) antagonist (IC50: 6 nM); recommended tool compound for HER2 selective inhibition

J Nagasawa et al. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int. J. Urol. 2006, 13(5), 587-592.

S Yoshida et al. Tak-165, a selective inhibitor of HER2 tyrosine kinase: 2. Mechanism of antitumor activity on HER2 signal transduction pathway. Proc. Am. Assoc. Can. Res. 2002, 43, 3898.

JC Uitdehaag et al. A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets. Br. J. Pharmacol. 2012, 166, 858–876.

Cell Signaling & Oncology ErbB2-HER2 RTK class I; EC 2.7.10.1

ErbB2/HER2 kinase inhibitor

Chemical name

(E)-4-((4-(4-(1H-1,2,3-triazol-1-yl)butyl)phenyl1H-1,2,3-triazol-1-yl)butyl)phenoxy)methyl)-2-(4-(trifluoromethyl)styryl)oxazole

Parent CAS No.

[366017-09-6]

产品资料